|Articles|February 1, 2001

February 2001
Volume 7
Issue 2

Cost-Effective Treatment of Depression with Selective Serotonin Reuptake Inhibitors

Author(s)Peter J. Panzarino, Jr, MD, David B. Nash, MD, MBA

Download PDF: Cost-Effective Treatment of Depression with Selective Serotonin Reuptake Inhibitors

Articles in this issue

over 25 years ago

Article

Professional Advice and Readiness to Change Behavioral Risk Factors Among Members of a Managed Care Organization

over 25 years ago

Article

Comparison of Cesarean Section Rates in Fee-for-Service Versus Managed Care Patients in the Ohio Medicaid Population, 1992-1997

over 25 years ago

Article

Predictive Power of a Risk-Assessment Questionnaire Across Different Disease States: Results in an Elderly Managed Care Enrolled Population

over 25 years ago

Article

A Satisfaction and Return-on-Investment Study of a Nurse Triage Service

over 25 years ago

Article

Studied Demonstrating Improved Outcomes in Patients with Asthma: A 10-Year Review

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Cost-Effective Treatment of Depression with Selective Serotonin Reuptake Inhibitors

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Cost-Effective Treatment of Depression with Selective Serotonin Reuptake Inhibitors

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors